EUVIMEDOpdag EUVIMED
Netzwerk-MetaanalyseSystematische ÜbersichtOpen access · CC BY 4.0

Network and Pairwise Meta‐Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus

Xuejiao Ye, Qian Wu iD, Linye Hou, Xinzheng Hou, Yingtian Yang iD, Chenyan Yang, Mingyu Huang, Shihan Wang iD

Diabetes/Metabolism Research and Reviews · 2026-07 · 42 (5)

DOI: 10.1002/dmrr.70202 ↗

At a glance

Netzwerk-Metaanalyse in Diabetes/Metabolism Research and Reviews, published online on 2026-07-15. Written by Xuejiao Ye and 7 co-authors. Institution: China Academy of Chinese Medical Sciences Guang'Anmen Hospital, Beijing, China. Major MEDLINE topics: Atrial Fibrillation, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents. 80 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation, Chinese Academy of Traditional Chinese Medicine's Major Tackling Project of Science and Technology Innovation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

To evaluate the atrial fibrillation (AF) risk of sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i), glucagonlike peptide‐1 receptor agonists (GLP‐1RA) and dipeptidyl peptidase‐4 inhibitors (DPP‐4i) in patients with Type 2 Diabetes Mellitus (T2DM) with network meta‐analysis.

Methods

Systematic literature searches were conducted of MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and Clinical Trials.gov covering inception till January 31, 2026. Randomized control trials (RCTs) and cohort studies comparing SGLT‐2i, GLP‐1RA and DPP‐4i in diabetes were selected. We performed a network meta‐analysis to compare the three drugs indirectly. Results were reported as risk ration (RR) with corresponding 95% confidence interval (CI).

Results

4 RCTs and 21 cohort studies involving 2,171,267 patients were included. Compared with GLP‐1RA [RR with 95% CI: 0.86(0.79, 0.95), RR with 95% CI: 0.87(0.78, 0.97)] and DPP‐4i[RR with 95% CI: 0.80(0.74, 0.87), RR with 95% CI: 0.81(0.74, 0.88)], SGLT‐2i significantly reduced the risk of AF and new‐onset AF. While there were no significant difference in the risk of AF recurrence among SGLT‐2i, GLP‐1RA, and DPP‐4i[RR with 95% CI: 0.87(0.68, 1.12), RR with 95% CI: 0.80(0.61, 1.05), RR with 95% CI: 0.92(0.63, 1.33)]. There were also no significant difference in the risk of AF and new‐onset AF between GLP‐1RA and DPP‐4i[RR with 95% CI: 0.93(0.84, 1.03), RR with 95% CI: 0.93(0.83, 1.04)].

Conclusions

The management of T2DM involves the prevention of subsequent cardiovascular complications. The results of this network meta‐analysis indicate that SGLT2i is associated with a lower risk of AF in T2DM patients compared to GLP‐1RA and DPP‐4i. Sensitivity analysis further confirms that SGLT‐2i significantly reduces the risk of AF recurrence statistically. These finding suggests that SGLT‐2i should be considered as a preferred antidiabetic regimen for patients with T2DM at high risk of AF.

Subjects

MeSH terms (MEDLINE)

Atrial FibrillationDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsHumansGlucagon-Like Peptide-1 Receptor AgonistsRisk Factors

Author keywords

DPP‐4 inhibitorsGLP‐1 receptor agonistSGLT‐2 inhibitorsatrial fibrillationnetwork meta‐analysistype 2 diabetes mellitus

Substances

Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Authors and institutions

  • China Academy of Chinese Medical Sciences Guang'Anmen Hospital, Beijing, China.
  • Beijing University of Chinese Medicine, Beijing, China.

ORCID profiles: Qian Wu, Yingtian Yang, Shihan Wang

Funding

  • National Natural Science Foundation of China
  • Beijing Municipal Natural Science Foundation
  • Chinese Academy of Traditional Chinese Medicine's Major Tackling Project of Science and Technology Innovation

Cite

APA

Ye, X., Wu, Q., Hou, L., Hou, X., Yang, Y., Yang, C., Huang, M., & Wang, S. (2026). Network and Pairwise Meta‐Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus. Diabetes/Metabolism Research and Reviews, 42(5). https://doi.org/10.1002/dmrr.70202

Vancouver

Ye X, Wu Q, Hou L, Hou X, Yang Y, Yang C, et al. Network and Pairwise Meta‐Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus. Diabetes/Metabolism Research and Reviews. 2026;42(5). doi:10.1002/dmrr.70202

BibTeX
@article{Ye2026,
  author = {Ye, Xuejiao and Wu, Qian and Hou, Linye and Hou, Xinzheng and Yang, Yingtian and Yang, Chenyan and Huang, Mingyu and Wang, Shihan},
  title = {Network and Pairwise Meta‐Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2026},
  volume = {42},
  number = {5},
  doi = {10.1002/dmrr.70202}
}
Start for free →